Differential Expression of Polyamine Pathways in Human Pancreatic Tumor Progression and Effects of Polyamine Blockade on Tumor Microenvironment

• Published in: Cancers Vol. 13; no. 24; p. 6391
• Main Authors: Nakkina, Sai Preethi, Gitto, Sarah B, Pandey, Veethika, Parikh, Jignesh G, Geerts, Dirk, Maurer, Hans Carlo, Olive, Kenneth P, Phanstiel, 4th, Otto, Altomare, Deborah A
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 20.12.2021; MDPI
• Subjects: Adenocarcinoma; Biosynthesis; Cancer therapies; CD86 antigen; Datasets; Gene expression; Genomes; Homeostasis; Immunotherapy; Laboratory animals; Lymphocytes T; Macrophages; Medical prognosis; Medical research; Melanoma; Metabolism; Pancreatic cancer; Patients; Polyamines; Prognosis; Stromal cells; Tumor cells; Tumor microenvironment; Tumors; United States > US; CD86; polyamine blockade therapy; survival; polyamine metabolism; macrophage; polyamine transport inhibitor; DFMO; tumor microenvironment; immune suppression; pancreatic ductal adenocarcinoma
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13246391

Pancreatic cancer is the fourth leading cause of cancer death. Existing therapies only moderately improve pancreatic ductal adenocarcinoma (PDAC) patient prognosis. The present study investigates the importance of the polyamine metabolism in the pancreatic tumor microenvironment. Relative mRNA expression analysis identified differential expression of polyamine biosynthesis, homeostasis, and transport mediators in both pancreatic epithelial and stromal cells from low-grade pancreatic intraepithelial neoplasia (PanIN-1) or primary PDAC patient samples. We found dysregulated mRNA levels that encode for proteins associated with the polyamine pathway of PDAC tumors compared to early lesions. Next, bioinformatic databases were used to assess expression of select genes involved in polyamine metabolism and their impact on patient survival. Higher expression of pro-polyamine genes was associated with poor patient prognosis, supporting the use of a polyamine blockade therapy (PBT) strategy for inhibiting pancreatic tumor progression. Moreover, PBT treatment of syngeneic mice injected intra-pancreatic with PAN 02 tumor cells resulted in increased survival and decreased tumor weights of PDAC-bearing mice. Histological assessment of PBT-treated tumors revealed macrophage presence and significantly increased expression of CD86, a T cell co-stimulatory marker. Collectively, therapies which target polyamine metabolism can be used to disrupt tumor progression, modulate tumor microenvironment, and extend overall survival.